“`html
Alcon (ALC) reported a year-to-date stock decline of 8.4%, compared to an 11.4% decline in its industry and a 13.3% rise in the S&P 500.
The company’s market capitalization stands at $43.49 billion, with earnings surpassing estimates in three of the last four quarters, averaging a 4.6% surprise. The Zacks Consensus Estimate for 2025 earnings per share has dropped 0.3% to $3.09, while 2025 revenue estimates are set at $10.35 billion, reflecting a 5.3% increase from last year.
With ongoing macroeconomic pressures including $27 million in tariff-related charges in Q2 2025, and anticipated costs of $100 million for the year, Alcon’s operations remain vulnerable. The company’s Surgical and Vision Care segments are expected to drive growth, but intense competition poses challenges for market share retention.
“`
